ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Chemours’ stock rebounds

by Marc S. Reisch
July 18, 2016 | APPEARED IN VOLUME 94, ISSUE 29

Chemours’s stock rose 16% on July 8 following an Ohio jury’s decision to award punitive damages of $500,000, lower than investors expected, in a testicular cancer case. Two days earlier, the firm’s stock had plummeted 22% when the jury awarded $5.1 million in compensatory damages to the cancer victim, who claimed drinking water contaminated with perfluorooctanoic acid (PFOA) from Chemours’s Parkersburg, W.Va., plant caused his illness. DuPont, which spun off Chemours a year ago, is named as the defendant in the cancer case and in 3,500 other cases claiming injury because of the contaminated water. The spin-off agreement called for Chemours to indemnify DuPont for legal costs. But in statements following the trial, Chemours pointed out that DuPont is directly liable for judgments and that Chemours may not have to pay in some unspecified instances. In a note to clients, Jefferies stock analyst Laurence Alexander says he expects Chemours will negotiate a cost-share arrangement with DuPont.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment